Citations

Clear

124 citation(s) found for "Storm, A".

Utility of methylated DNA markers for the diagnosis of malignant biliary strictures
Cooley, Matthew A. , Schneider, Amber, Fritcher, Emily G. Barr , Milosevic, Dragana , Levy, Michael J. , Bridgeman, Amber R. , Martin, John A. , Petersen, Bret T. , Dayyeh, Barham K. Abu , Law, Ryan , Garimella, Vishal, Jenkins, Sarah M. , Yin, Jun, Roberts, Lewis R. , Kipp, Benjamin R. , Ferrándiz‐Pulido, Carla , Schneider, Amber R, Abu Dayyeh, Barham K , Storm, Andrew C , Law, Ryan J, Vargas, Eric J , Roberts, Lewis R , Kipp, Benjamin , Chandrasekhara, Vinay , Barr Fritcher, Emily G , Bridgeman, Amber R , Levy, Michael J. , Storm, Andrew C. , Vargas, Eric J. , Zemla, Tyler , Gores, Gregory J. , Chandrasekhara, Vinay

Mayo Clinic

Hepatology | June 21, 2024 | Volume: 81 | Issue: 2 | Pages: 453-464

10.1097/hep.0000000000000970 | PMID 38905442 Get It

Background and Aims: Early identification of malignant biliary strictures (MBSs) is challenging, with up to 20% classified as indeterminants after preliminary testing and tissue sampling with endoscopic retrograde cholangiopancreatography. We aimed to evaluate the use of methylated DNA markers (MDMs) from biliary brushings to enhance MBS detection in a prospective cohort. Approach: Candidate MDMs were evaluated for their utility in MBS diagnosis through a series of discovery and validation phases. DNA was extracted from biliary brushing samples, quantified, bisulfite-converted, and then subjected to methylation-specific droplet digital polymerase chain reaction. Patients were considered to have no malignancy if the sampling was negative and there was no evidence of malignancy after 1 year or definitive negative surgical histopathology. Results: Fourteen candidate MDMs were evaluated in the discovery phase, with top-performing and new markers evaluated in the technical validation phase. The top 4 MDMs were TWIST1, HOXA1, VSTM2B, and CLEC11A, which individually achieved AUC values of 0.82, 0.81, 0.83, and 0.78, respectively, with sensitivities of 59.4%, 53.1%, 62.5%, and 50.0%, respectively, at high specificities for malignancy of 95.2%–95.3% for the final biologic validation phase. When combined as a panel, the AUC was 0.86, achieving 73.4% sensitivity and 92.9% specificity, which outperformed cytology and fluorescence in situ hybridization (FISH). Conclusions: The selected MDMs demonstrated improved performance characteristics for the detection of MBS compared to cytology and FISH. Therefore, MDMs should be considered viable candidates for inclusion in diagnostic testing algorithms.
University of Washington Quality of Life subdomain outcomes after treatment of sinonasal malignancy: A prospective, multicenter study
Maoz, Sabrina L. , Golzar, Autreen , Hwang, Peter H. , Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chan, Erik, Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Lazor, Jillian W. , Nabavizadeh, Ali , Adappa, Nithin D. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Sim, Myung‐Shin , Choby, Garret , Hwang, Peter H , Wang, Eric W , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Kingdom, Todd T , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Beswick, Daniel , Maoz, Sabrina L , Choby, Garret , Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Pinheiro‐Neto, Carlos , Fischer, Jakob L. , Abuzeid, Waleed M. , Nayak, Jayakar V. , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D. , Beswick, Daniel M.

Mayo Clinic

International Forum of Allergy & Rhinology | June 17, 2024 | Volume: 14 | Issue: 10 | Pages: 1568-1581

10.1002/alr.23386 | PMID 38884276 Get It

AbstractPurposeSinonasal malignancies (SNMs) adversely impact patients’ quality of life (QOL) and are frequently identified at an advanced stage. Because these tumors are rare, there are few studies that examine the specific QOL areas that are impacted. This knowledge would help improve the care of these patients.MethodsIn this prospective, multi‐institutional study, 273 patients with SNMs who underwent definitive treatment with curative intent were evaluated. We used the University of Washington Quality of Life (UWQOL) instrument over 5 years from diagnosis to identify demographic, treatment, and disease‐related factors that influence each of the 12 UWQOL subdomains from baseline to 5 ‐years post‐treatment.ResultsMultivariate models found endoscopic resection predicted improved pain (vs. nonsurgical treatment CI 2.4, 19.4, p = 0.01) and appearance versus open (CI 27.0, 35.0, p < 0.001) or combined (CI 10.4, 17.1, p < 0.001). Pterygopalatine fossa involvement predicted worse swallow (CI −10.8, −2.4, p = 0.01) and pain (CI −17.0, −4.0, p < 0.001). Neck dissection predicted worse swallow (CI −14.8, −2.8, p < 0.001), taste (CI −31.7, −1.5, p = 0.02), and salivary symptoms (CI −28.4, −8.6, p < 0.001). Maxillary involvement predicted worse chewing (CI 9.8, 33.2; p < 0.001) and speech (CI −21.8, −5.4, p < 0.001) relative to other sites. Advanced T stage predicted worse anxiety (CI −13.0, −2.0, p = 0.03).ConclusionsSurgical approach, management of cervical disease, tumor extent, and site of involvement impacted variable UWQOL symptom areas. Endoscopic resection predicted better pain, appearance, and chewing compared with open. These results may aid in counseling patients regarding potential QOL expectations in their SNM treatment and recovery course.
Celiac artery mesenteric fat measurement with endosonography (CAMEUS) reliably correlates with obesity and related comorbidities
Bazerbachi, Fateh , Baroud, Serge , Levy, Michael J. , Maselli, Daniel B. , Bofill-García, Aliana, Law, Ryan , Chandrasekhara, Vinay , Gleeson, Ferga C. , Rajan, Elizabeth , Iyer, Prasad G. , Watt, Kymberly D. , Law, Ryan J, Chandrasekhara, Vinay , Bazerbachi, F , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Gastroenterology Report | April 26, 2024 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1093/gastro/goae039 | PMID 38681751 Get It

Abstract Background Visceral fat represents a metabolically active entity linked to adverse metabolic sequelae of obesity. We aimed to determine if celiac artery mesenteric fat thickness can be reliably measured during endoscopic ultrasound (EUS), and if these measurements correlate with metabolic disease burden. Methods This was a retrospective analysis of patients who underwent celiac artery mesenteric fat measurement with endosonography (CAMEUS) measurement at a tertiary referral center, and a validation prospective trial of patients with obesity and nonalcoholic steatohepatitis who received paired EUS exams with CAMEUS measurement before and after six months of treatment with an intragastric balloon. Results CAMEUS was measured in 154 patients [56.5% females, mean age 56.5 ± 18.0 years, body mass index (BMI) 29.8 ± 8.0 kg/m2] and was estimated at 14.7 ± 6.5 mm. CAMEUS better correlated with the presence of non-alcoholic fatty liver disease (NAFLD) (R2 = 0.248, P &lt; 0.001) than BMI (R2 = 0.153, P &lt; 0.001), and significantly correlated with metabolic parameters and diseases. After six months of intragastric balloon placement, the prospective cohort experienced 11.7% total body weight loss, 1.3 points improvement in hemoglobin A1c (P = 0.001), and a 29.4% average decrease in CAMEUS (−6.4 ± 5.2 mm, P &lt; 0.001). CAMEUS correlated with improvements in weight (R2 = 0.368), aspartate aminotransferase to platelet ratio index (R2 = 0.138), and NAFLD activity score (R2 = 0.156) (all P &lt; 0.05). Conclusions CAMEUS is a novel measure that is significantly correlated with critical metabolic indices and can be easily captured during routine EUS to risk-stratify susceptible patients. This station could allow for EUS access to sampling and therapeutics of this metabolic region.
Applicability of individualized metabolic surgery score for prediction of diabetes remission after endoscopic sleeve gastroplasty
Gala, Khushboo , Brunaldi, Vitor , Ghusn, Wissam , Vargas, Eric J. , Storm, Andrew C. , Acosta, Andrés , Dayyeh, Barham K. Abu

Mayo Clinic

Therapeutic Advances in Gastrointestinal Endoscopy | April 26, 2024 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/26317745241247175 | PMID 38682042 Get It

Background: Endoscopic sleeve gastroplasty (ESG) is a safe and effective obesity treatment. The individualized metabolic score (IMS) is a validated score that uses preoperative variables predicting T2D remission (DR) in bariatric surgery. Objectives: We evaluated the applicability of using the IMS score to predict DR in patients after ESG. Design/Methods: We performed a retrospective review of patients with obesity and T2D who underwent ESG. We calculated DR, IMS score, and severity, and divided patients based on IMS category. Results: The cohort comprised 20 patients: 25% (5) mild, 55% (11) moderate, and 20% (4) severe IMS stages. DR was achieved in 60%, 45.5%, and 0% of patients with mild, moderate, and severe IMS scores ( p = 0.08), respectively. IMS score was significantly associated with DR ( p = 0.03), with the area under the curve of the receiver operating characteristic for predicting DR 0.85. Conclusion: These pilot data demonstrate that the IMS score appears to be useful in predicting DR after ESG.
Endoscopic Ultrasound-based Shear Wave Elastography for Detection of Advanced Liver Disease
Chin, Jerry Yung‐Lun , Kaur, Jyotroop, Law, Ryan , Garimella, Vishal, Levy, Michael J. , Dierkhising, Ross , Venkatesh, Sudhakar, AbiMansour, Jad P. , Vargas, Eric J. , Dayyeh, Barham K. Abu , Storm, Andrew C. , Allen, Alina M. , Venkatesh, Sudhakar K. , Chandrasekhara, Vinay

Mayo Clinic

Journal of Clinical Gastroenterology | April 22, 2024 | Volume: 59 | Issue: 3 | Pages: 256-261

10.1097/mcg.0000000000002013 | PMID 38648501 Get It

Background and Aims: Endoscopic ultrasound shear wave elastography (EUS-SWE) is a novel modality for liver stiffness measurement. The aims of this study are to evaluate the performance and reliability of EUS-SWE for detecting advanced liver disease in a prospective cohort. Methods: EUS-SWE measurements were prospectively obtained from patients undergoing EUS between August 2020 and March 2023. Liver stiffness measurements were compared between patients with and without advanced liver disease (ALD), defined as stage ≥3, to determine diagnostic accuracy for advanced fibrosis and portal hypertension. Logistic regression was performed to identify variables that impact the reliability of EUS-SWE readings. Select patients underwent paired magnetic resonance elastography (MRE) for liver fibrosis correlation. Results: Patients with ALD demonstrated higher liver stiffness compared to healthy controls (left lobe: 17.6 vs. 12.7 kPa, P <0.001; median right lobe: 24.8 vs. 11.0 kPa, P <0.001). The area under the receiver operator characteristic (AUROC) for the detection of ALD was 0.73 and 0.80 for left and right lobe measurements, respectively. General anesthesia was associated with reliable EUS-SWE liver readings (odds ratio: 2.73, 95% CI: 1.07-7.39, P =0.040). Left lobe measurements correlated significantly with MRE with an increase of 0.11 kPa (95% CI: 0.05-0.17 kPA) for every 1 kPa increase on EUS-SWE. D. Conclusions: SWE is a promising technology that can readily be incorporated into standard EUS examinations for the assessment of ALD.
Electrical storm after left ventricular assist device (LVAD) implantation
Karikalan, Suganya Arunachalam , Zhang, Nan , Masry, Hicham El , Killu, Ammar M. , DeSimone, Christopher V. , Deshmukh, Abhishek , Sorajja, Dan , Scott, Luis R. , Cha, Yong‐Mei , Lee, Justin Z. , Karikalan, Suganya , Tan, Min Choon , El Masry, Hicham , Killu, Ammar M , DeSimone, Christopher V , Deshmukh, Abhishek J , Cha, Yong-Mei , McLeod, Christopher J. , Srivathsan, Komandoor

Mayo Clinic

Journal of Cardiovascular Electrophysiology | April 9, 2024 | Volume: 35 | Issue: 6 | Pages: 1196-1202

10.1111/jce.16275 | PMID 38590268 Get It

AbstractIntroductionVentricular tachycardia storm or electrical storm (ES) is a common complication following left ventricular assist device (LVAD) implantation. The factors contributing to ES and outcomes are less studied. The study aimed to determine the factors associated with ES and the probability of survival in patients undergoing LVAD in three tertiary centers over a span of 15 years.MethodsWe performed a retrospective cohort study on all patients who underwent LVAD implantation at the Mayo Clinic (Rochester, Phoenix, and Jacksonville) from January 1, 2006 to December 31, 2020. ES was defined as ≥3 episodes of sustained ventricular tachycardia over a period of 24 h with no identifiable reversible cause. Detailed chart reviews of the electronic health records within the Mayo Clinic and outside medical records were performed.ResultsA total of 883 patients who underwent LVAD implantation were included in our study. ES occurred in 7% (n = 61) of patients with a median of 13 days (interquartile range [IQR]: 5–297 days) following surgery. We found 57% of patients (n = 35) developed ES within 30 days, while 43% (n = 26) patients developed ES at a median of 545 (IQR 152–1032) days after surgery. Following ES, 26% of patients died within 1 year. Patients with ES had a significant association with a history of ventricular arrhythmias and implantable cardioverter defibrillator (ICD) shocks before the procedure. ES was significantly associated with reduced survival compared to patients without ES (hazards ratio [HR]: 1.92, 95% CI: 1.39–2.64, p < .001).ConclusionFollowing LVAD implantation, the rate of ES was 7% with majority of ES occurring within 30 days of LVAD. Risk factors for ES included pre‐implant history of ventricular arrhythmias and ICD shock. ES was significantly associated with reduced survival compared to patients without ES.
A Perfect Storm: Vibrio Necrotizing Fasciitis During Hurricane Season in Florida
Young, Maia C. , Zuberi, Eric , Seim, Lynsey A. , Hedges, Mary S. , James, Courtney L , Seim, Lynsey , Hedges, Mary S

Mayo Clinic

Annals of Internal Medicine: Clinical Cases | February 20, 2024 | Volume: 3 | Issue: 2 | Pages: No page available

10.7326/aimcc.2023.1204 Get It

SNOT‐22 subdomain outcomes following treatment for sinonasal malignancy: A prospective, multicenter study
Grimm, David R. , Beswick, Daniel M. , Maoz, Sabrina L. , Chan, Erik, Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Adappa, Nithin D. , Patel, Zara M. , Sim, Myung‐Shin , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Hwang, Peter H. , Wang, Eric W , Choby, Garret , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Hwang, Peter H , Beswick, Daniel , Grimm, David R , Maoz, Sabrina L , Choby, Garret , Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Abuzeid, Waleed M. , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D.

Mayo Clinic

International Forum of Allergy & Rhinology | February 19, 2024 | Volume: 14 | Issue: 8 | Pages: 1314-1326

10.1002/alr.23338 | PMID 38372441 Get It

AbstractBackgroundPatients with sinonasal malignancy (SNM) present with significant sinonasal quality of life (QOL) impairment. Global sinonasal QOL as measured by the 22‐item Sinonasal Outcomes Test (SNOT‐22) has been shown to improve with treatment. This study aims to characterize SNOT‐22 subdomain outcomes in SNM.MethodsPatients diagnosed with SNM were prospectively enrolled in a multi‐center patient registry. SNOT‐22 scores were collected at the time of diagnosis and through the post‐treatment period for up to 5 years. Multivariable regression analysis was used to identify drivers of variation in SNOT‐22 subdomains.ResultsNote that 234 patients were reviewed, with a mean follow‐up of 22 months (3 months–64 months). Rhinologic, psychological, and sleep subdomains significantly improved versus baseline (all p < 0.05). Subanalysis of 40 patients with follow‐up at all timepoints showed statistically significant improvement in rhinologic, extra‐nasal, psychological, and sleep subdomains, with minimal clinically important difference met between 2 and 5 years in sleep and psychological subdomains. Adjuvant chemoradiation was associated with worse outcomes in rhinologic (adjusted odds ratio (5.22 [1.69–8.66])), extra‐nasal (2.21 [0.22–4.17]) and ear/facial (5.53 [2.10–8.91]) subdomains. Pterygopalatine fossa involvement was associated with worse outcomes in rhinologic (3.22 [0.54–5.93]) and ear/facial (2.97 [0.32–5.65]) subdomains. Positive margins (5.74 [2.17–9.29]) and surgical approach—combined versus endoscopic (3.41 [0.78–6.05])—were associated with worse psychological outcomes. Adjuvant radiation (2.28 [0.18–4.40]) was associated with worse sleep outcomes.ConclusionsSinonasal QOL improvements associated with treatment of SNM are driven by rhinologic, extra‐nasal, psychological, and sleep subdomains.
Practice patterns and outcomes of endoscopic sleeve gastroplasty based on provider specialty
Gala, Khushboo, Brunaldi, Vitor , McGowan, Christopher , Sharaiha, Reem Z. , Maselli, Daniel B. , VanderWel, Brandon , Kedia, Prashant , Ujiki, Michael , Wilson, Erik B., Vargas, Eric J , Storm, Andrew C , Gala, Khushboo , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | January 23, 2024 | Volume: 12 | Issue: 02 | Pages: E253-E261

10.1055/a-2251-3738 | PMID 38415023 Get It

Abstract Background and study aims Endoscopic sleeve gastroplasty (ESG) is performed in clinical practice by gastroenterologists and bariatric surgeons. Given the increasing regulatory approval and global adoption, we aimed to evaluate real-world outcomes in multidisciplinary practices involving bariatric surgeons and gastroenterologists across the United States. Patients and methods We included adult patients with obesity who underwent ESG from January 2013 to August 2022 in seven academic and private centers in the United States. Patient and procedure characteristics, serious adverse events (SAEs), and weight loss outcomes up to 24 months were analyzed. SPSS (version 29.0) was used for all statistical analyses. Results A total of 1506 patients from seven sites included 235 (15.6%) treated by surgeons and 1271 (84.4%) treated by gastroenterologists. There were no baseline differences between groups. Gastroenterologists used argon plasma coagulation for marking significantly more often than surgeons (P<0.001). Surgeons placed sutures in the fundus in all instances whereas gastroenterologist placed them in the fundus in less than 1% of the cases (P<0.001>). Procedure times were significantly different between groups, with surgeons requiring approximately 20 minutes more during the procedure than gastroenterologists (P<0.001). Percent total body weight loss (%TBWL) and percent responders achieving >10 and >15% TBWL were similar between the two groups at 12, 18, and 24 months. Rates of SAEs were low and similar at 1.7% for surgeons and 2.7% for gastroenterologists (P>0.05). Conclusions Data from a large US cohort show significant and sustained weight loss with ESG and an excellent safety profile in both bariatric surgery and gastroenterology practices, supporting the scalability of the procedure across practices in a multidisciplinary setting.
Incidence of Post-ERCP Pancreatitis in Patients Receiving Diclofenac Versus Indomethacin Prophylaxis
Yamparala, A., Sathi, Thanmay, Harmsen, William S. , Lemke, Emily, Dayyeh, Barham Abu, Bofill-García, Aliana, Martin, John A. , Petersen, Bret T. , Topazian, Mark , Chandrasekhara, V., Law, Ryan , Janssens, Laurens , Lemke, E., Lévy, Michaël , Petersen, Bret T. , Storm, Andrew C. , Valls, E. Vargas

Mayo Clinic

Endoscopy | November 9, 2023 | Volume: 55 | Issue: S 02 | Pages: S156-S156

10.1055/s-0043-1765392 Get It